Gossamer Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 8, 2023, specifically the Company's 2023 Annual Meeting of Stockholders. Gossamer Bio, Inc. is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on the Nasdaq Global Select Market under the symbol GOSS.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
The primary material event reported is the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation. This amendment eliminates the personal liability of the Company's officers for monetary damages for breach of fiduciary duty, to the extent permitted by Delaware General Corporation Law. The amendment became effective upon the filing of the Certificate of Amendment with the Secretary of State of Delaware on June 8, 2023.
Voting Results and Management Commentary
Stockholders voted on four matters at the Annual Meeting. The results were as follows:
- Election of Directors: Two Class II directors were re-elected for a three-year term.
- Faheem Hasnain: 53,389,848 votes For; 5,574,754 votes Withheld.
- Russell Cox: 42,130,560 votes For; 16,834,042 votes Withheld.
- Ratification of Auditors: The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
- Result: 76,279,156 votes For; 72,683 votes Against.
- Executive Compensation (Say-on-Pay): The advisory approval of named executive officer compensation received mixed support.
- Result: 38,901,355 votes For; 19,975,931 votes Against.
- Amendment to Certificate of Incorporation: The proposal to limit officer liability was approved.
- Result: 55,967,264 votes For; 2,924,078 votes Against.
There were 17,454,308 broker non-votes recorded for the director elections, the executive compensation vote, and the amendment vote.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of the liability limitation for officers.
- Review the 2023 Proxy Statement for detailed context on the significant number of votes withheld for director Russell Cox and the "Against" votes on executive compensation.
- Confirm the Company's latest financial position by reviewing the most recent Form 10-K or 10-Q, as this 8-K contains no financial data.
- Monitor future filings for any updates regarding the Company's cash runway or capital raise activities, given the biotech sector's typical capital intensity.